SecBot SecBot
SECBOTREPLAY Home › Report › INKT

INKT · MiNK Therapeutics announced it will report Q4 and full-year 2025…

MiNK Therapeutics · PRESS-RELEASE filed Mar 17, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 17, 2026 at 07:30 ET

MiNK Therapeutics announced it will report Q4 and full-year 2025 financial results on March 31, 2026, alongside a corporate update on clinical progress and its iNKT cell therapy platform. The press release highlights a new collaboration with C-Further and the University of Southampton to develop a PRAME-targeted iNKT therapy for pediatric cancers, bringing non-dilutive funding and strategic validation. However, no actual financial data was disclosed in this announcement.

  • MiNK Therapeutics will report Q4 and full-year 2025 financial results on March 31, 2026, before market open.
  • Company to host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update.
  • New collaboration with C-Further and University of Southampton on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers.
  • Collaboration includes non-dilutive funding and potential downstream commercial revenue.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access